GeneFirst is a molecular diagnostics company aiming to become the go to provider in the field of oncology for the fastest, simplest and most reliable molecular testing solutions. Founded in 2011, GeneFirst was born out of a passion for scientific discoveries and recognition for the importance of providing accurate testing to improve patient care.

Focusing on empowering clinical decision making, our mission is to support healthier lives by exploiting our in-house expertise to develop and offer the right technology for the right test.

XCeloSeq®, powered by ATOM-Seq®, is GeneFirst’s targeted, comprehensive NGS panel for the detection of actionable fusion targets in cancers. These enrichment kits generate high quality sequencing libraries for cancer detection from liquid biopsy and FFPE RNA samples.

XCeloSeq® is ligation free, simple, efficient and flexible, suited to highly challenging clinical materials such as RNA extractions from FFPE, high quality tissue samples and cell-free RNA, making this kit the practical choice for cancer testing.

The kit uses unique protocol-based enhancements for sensitivity, specificity, and error correction, allowing for the highest sample retention and capture efficiency. The streamlined 7.25-hour protocol improves laboratory efficiency.

Find out more about GeneFirst:

Website: www.genefirst.com

Telephone: +44(0) 18 6540 7400

LinkedIn: https://il.linkedin.com/company/genefirst-ltd

Twitter: https://www.twitter.com/genefirst